Clinical trial · Observational
A Multicenter, Cross-sectional Study on the Quality of Life in Long-term Survival Esophageal Cancer Patients After Radical Radiochemotherapy/Radiotherapy
NCT05828875CI-TRIAL-00067844unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is a multicenter cross-sectional survey of esophageal cancer patients who underwent radical chemoradiotherapy/radiotherapy from July 2017 to July 2020 in various medical centers, and who survived without disease progression at the time of the survey. The purpose of this study is to evaluate the current quality of life, as well as the incidence of long-term toxic side effects, nutritional status, and psychological status of esophageal cancer patients cured by radiotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Assessing the Current Quality of Life Status of Esophageal Cancer Patients Who Have Undergone Radical Chemoradiotherapy/Radiotherapy and Long-term Survival | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| questionnaire investigation | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Quality of Life Assessment survey
- timeFrame
- Two years after the end of radiotherapy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Voluntarily accept this survey and research; * The age at the time of radiotherapy is between 18-75 years old, and the age at the time of investigation is\<80 years old; * Histologically confirmed esophageal squamous cell carcinoma without undergoing surgical resection; * Received radical chemoradiotherapy/radiotherapy from July 2017 to July 2020, currently alive and without disease progression; * Radiotherapy dose ≥ 45Gy. Exclusion Criteria: * Patients who do not cooperate with this survey; * Patients who have died at the time of investigation; * Patients who experience tumor progression within the time frame from the end of radiotherapy to receiving this survey; * Patients diagnosed with other malignant tumors within the time frame from the end of radiotherapy to receiving this survey; * Patients with incorrect contact information and missing visits
References
Publications (0)
Data not yet available
No reference posted for this study.